Dr Mohiuddin is a Professor of Surgery and Director of Cardiac Xenotransplantation Program at University of Maryland Baltimore, Baltimore, Maryland, USA. Dr Mohiuddin also have a joint appointment in the graduate school of University of Maryland where he mentors PhD students. Dr Mohiuddin also serves on various committees at his current institution including School of Medicine council. Before joining UMB in June 2017, Dr Mohiuddin served as chief of transplantation section of Cardiothoracic Surgery Research Program and Senior Scientist at the National Heart Lung and Blood Institute of the National Institutes of Health. Before, NIH, he held faculty positions at University of Pennsylvania, Philadelphia and Rush University, Chicago. Dr. Mohiuddin is involved in the field of xenotransplantation since 1992 and has been instrumental in starting the xenotransplantation research programs at the above institutions.
Dr. Mohiuddin’s primary interest is in understanding the role of B lymphocytes in Transplantation, especially xenograft rejection. His other interests include transplantation tolerance and immune modulation. He has made several contributions to the fields of transplantation and xenotransplantation with over 120 publications and over 100 abstracts as well as numerous presentations. His group holds the record of longest heterotopic xenograft survival in a large animal model. The immunosuppressive regimen developed under his leadership is now used widely throughout the xenotransplantation field.
Dr. Mohiuddin is an elected councilor of International Xenotransplantation Association / TTS. He is a member of prestigious societies; The Transplantation Society and American Society of Transplant Physicians. He reviews manuscripts for journals; Transplantation, Transplant Immunology, xenotransplantation, Journal of Heart and Lung Transplantation, etc. He has received several NIH and non-NIH grants during his academic career. His recent work in cardiac xenotransplantation was highlighted and acknowledged widely in press throughout the world. He is currently overseeing a multi-million dollar cardiac xenotransplantation project funded by United Therapeutics at University of Maryland.